Billions On The Line: Merck's HCV Patents Upheld In Gilead Lawsuit
This article was originally published in Scrip
Executive Summary
In a lawsuit that Gilead Sciences Inc. filed after receiving a request from Merck & Co. Inc. for royalties from Gilead's blockbuster hepatitis C drug Sovaldi (sofosbuvir), Merck may now be entitled to billions of dollars in royalties and damages after a jury validated the company's patents on March 22.